Immunome, Inc.
IMNM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $1 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 37.2% | 6.9% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 82.1% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,139.7% | -1,500.7% | -2,008.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,080.9% | -1,423.1% | -2,930.9% |
| EPS Diluted | -0.65 | -0.5 | -0.52 | -1.28 |
| % Growth | -30% | 3.8% | 59.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |